Alirocumab (PCSK9) Antibody, Monoclonal Cat. No.: 10-485

Availability: In stock

$0.00

No Image

 Price Options

$0.00
psi-iconSpecifications
IMMUNOGEN: Homo sapiens / PCSK9 [Homo sapiens]

psi-iconProperties
PURIFICATION:>95%
CLONALITY:Monoclonal
ISOTYPE:IgG1-kappa
CONJUGATE:Unconjugated
BUFFER:PBS buffer pH7.5
STORAGE CONDITIONS:Store at -80˚C

psi-iconAdditional Info
ALTERNATE NAMES:REGN727,SAR-236553,
USER NOTE:Optimal dilutions for each application to be determined by the researcher.
psi-iconBackground and References
BACKGROUND:Alirocumab is a biopharmaceutical that obtained FDA approval in July 2015 as a second line treatment for high cholesterol in adults whose LDL-cholesterol (LDL-C) is not controlled by the combination of diet and statin treatment. It is a human monoclonal antibody part of the family of the PCSK9 inhibitors which are a novel class of anticholesterol therapeutics. From this family, it was the first agent to receive FDA approval. The FDA approval was contingent on the completion of further clinical trials to better determine efficacy and safety. PCSK9 inhibition facilitates more LDL-C clearance from the blood.

ANTIBODIES FOR RESEARCH USE ONLY.

For additional information, visit ProSci's Terms & Conditions Page.